7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

1/5
Please reload

Featured Posts

MaxCyte Highlights Gram-Scale Antibody & Protein Production from Transient Transfection of CHO Cells and MaxCyte® VLX™ Large Scale Transfection System Launch

March 12, 2012

European Introduction of the MaxCyte® VLX™ Large Scale Transfection System at Informa's Cell Line Development and Engineering Conference in Cologne, February 13-17
 

Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is hosting a series of events at Informa's Cell Line Development and Engineering Meeting 2012 being held February 13-17 at the Radisson Blu Hotel in Cologne, Germany.

 

On February 13, Dr. Peer Heine of MaxCyte will present a talk entitled "Rapid production of high titer proteins in large volumes using scalable, transient transfection of mammalian and insect cells". Dr. Heine will provide case studies from users of the MaxCyte® STX™ Scalable Transfection System demonstrating the potential to achieve gram?scale antibody and protein production in appropriate biomanufacturing host cell lines, including CHO, with a simple 20-30 minute instrument run. In addition, MaxCyte will present a scientific poster entitled "MAb Production Using MaxCyte Electroporation for Large Scale Transient Transfection of CHO Cells".

 

At this meeting, MaxCyte will introduce the MaxCyte® VLX™ Large Scale Transfection System to Europe. The MaxCyte VLX has the capability to transfect up to 2E11 cells in less than 30 minutes with high efficiency and high viability, dramatically extending the gram?scale protein bioproduction capabilities of the current MaxCyte instrument product line.

 

"We are delighted to announce the gram?scale antibody and protein yields achieved by users of the MaxCyte STX in standard biomanufacturing cell lines, including CHO. Companies are no longer limited to settling for surrogate or non?relevant systems like HEK in order to generate enough protein or antibody for the development and screening of therapeutic biopharmaceuticals," says Douglas Doerfler, President, and CEO of MaxCyte. "We are also delighted to announce in Europe the introduction of the MaxCyte VLX for very large scale transient transfection, enabling high?yield protein production in any desired cell type, including CHO and Vero. The MaxCyte VLX dramatically increases the volume capability of our product line, enabling 200 billion cell transfection runs for the production of recombinant proteins, antibodies, virus-like particles (VLPs), virus-replicon particles (VRPs), and toxic and apoptotic proteins using the same patented flow electroporation platform as the well-proven MaxCyte® STX™ Scalable Transfection System."

 

About MaxCyte

 

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte® STX™ Scalable Transfection System and MaxCyte® VLX™ Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell?based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot scale.

 

For more information, http://www.maxcyte.com.

 

Tags:

Please reload

NEWS